Cardiac repair through direct reprogramming
Cell and tissue engineering, health, cardiac tissue, regenerative medicine, cellular reprogramming, delivery
Advancements in our ability to reprogram somatic cells from one cell type into another through the delivery of a defined set of factors or genetic material have led to a recent breakthrough in terms of reprogramming cardiac fibroblast cells into cardiomyocytes, in mice (in vitro and in vivo) and most recently, human cells (in vitro). These exciting discoveries offer significant potential in the future to repair damaged heart tissue post an acute myocardial infarct (AMI). However, the realisation of this potential is at present limited by 1.) the current use of delivery vehicles that are unable to be clinically translated (such a lentiviruses), and 2.) by the lack of capacity to rapidly screen genetic material for optimised and efficient direct reprogramming outcomes (current efficiencies are around 20%).
This project will address the first limitation to this becoming a therapeutic option for heart attack victims, through the development of tailored, cell-specific delivery vehicles designed for clinical translation and uptake. These delivery vehicles will be validated firstly using adult mouse heart cells (in vitro) and AMI models (in vivo) and thereafter, using human (iPSC-derived) heart tissue (in vitro). This project will be performed in collaboration with Associate Professor Ernst Wolvetang (AIBN) and Dr Enzo Porrello (School of Biomedical Sciences).
|Lead investigator||Professor Justin Cooper-White
|Research group||Cooper-White Group|